40,759 Shares in Pfizer Inc. (NYSE:PFE) Purchased by AssuredPartners Investment Advisors LLC

AssuredPartners Investment Advisors LLC purchased a new position in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 40,759 shares of the biopharmaceutical company's stock, valued at approximately $1,081,000.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Pfizer by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock worth $13,756,738,000 after purchasing an additional 2,285,276 shares in the last quarter. State Street Corp grew its stake in Pfizer by 1.2% in the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company's stock worth $8,405,930,000 after buying an additional 3,405,539 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Pfizer by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock valued at $3,392,342,000 after buying an additional 1,855,419 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Pfizer by 22.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock worth $1,101,713,000 after acquiring an additional 6,977,587 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Remove Ads

Insider Activity

In other news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company's stock.

Pfizer Stock Performance

PFE stock traded up $0.19 during midday trading on Friday, reaching $25.20. 32,322,049 shares of the company's stock traded hands, compared to its average volume of 39,037,478. The stock's 50-day moving average is $26.06 and its 200 day moving average is $26.92. The stock has a market cap of $142.93 billion, a P/E ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm posted $0.10 EPS. The firm's quarterly revenue was up 24.7% compared to the same quarter last year. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research reports. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group dropped their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.